The gastrointestinal tolerability and safety of oral bisphosphonates.

摘要: Oral bisphosphonates are effective for osteoporosis and other hyperresorptive bone disorders. Although well-tolerated in efficacy trials, some oral aminobisphosphonates have been associated with upper gastrointestinal intolerance injury postmarketing experience. Clinical trials often underestimate the rate of adverse events clinical practice, ethics prohibit direct evaluation toxicity high-risk patients. Accordingly, animal models endoscopy studies provide valuable insight. It is unclear whether variation ulcerogenic potential reflects differences dosing, formulation or chemical structure. Furthermore, relevance endoscopic lesions uncertain. Ongoing review will determine damage predict tolerability safety practice. However, physicians patients should consider risk factors oesophageal when initiating therapy.